Attenuation of microtubule associated protein-2 degradation after mild head injury by mexiletine and calpain-2 inhibitor

References

• Abu-Judeh H H, Parker R, Singh M, et al. SPET brain perfusion imaging in mild traumatic brain injury without loss of consciousness and normal computed tomography. Nucl Med Comm 1999; 20(6)505–510
   PubMedGoogle Scholar
• Caner H, Can A, Atalay B, et al. Early effects of mild brain trauma on the cytoskeletal proteins neurofilament160 and MAP2, and the preventive effects of mexilitine. Acta Neurochir (Wien) 2004; 146(6)611–621, discussion 621
   PubMedGoogle Scholar
• Kampfl A, Posmantur R, Nixon R, et al. mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J Neurochem 1996; 67(4)1575–1583
   PubMedGoogle Scholar
• Buki A, Siman R, Trojanowski J Q, Povlishock J T. The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury. J Neuropathol Exp Neurol 1999; 58(4)365–375
   PubMedGoogle Scholar
• Matus A. Microtubule-associated proteins: their potential role in determining neuronal morphology. Annu Rev Neurosci 1988; 11: 29–44
   PubMed Web of Science ®Google Scholar
• Geddes J F, Vowles G H, Nicoll J A, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol (Berl) 1999; 98(2)171–178
   PubMed Web of Science ®Google Scholar
• Jane J A, Steward O, Gennarelli T. Axonal degeneration induced by experimental noninvasive minor head injury. J Neurosurg 1985; 62(1)96–100
   PubMedGoogle Scholar
• Maxwell W L, Donnelly S, Sun X, Fenton T, Puri N, Graham D I. Axonal cytoskeletal responses to nondisruptive axonal injury and the short-term effects of posttraumatic hypothermia. J Neurotrauma 1999; 16(12)1225–1234
   PubMed Web of Science ®Google Scholar
• Saatman K E, Zhang C, Bartus R T, McIntosh T K. Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. J Cereb Blood Flow Metab 2000; 20(1)66–73
   PubMedGoogle Scholar
• Posmantur R, Kampfl A, Siman R, et al. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience 1997; 77(3)875–888
   PubMed Web of Science ®Google Scholar
• Jiang Q, Stys P K. Calpain inhibitors confer biochemical, but not electrophysiological, protection against anoxia in rat optic nerves. J Neurochem 2000; 74(5)2101–2107
   PubMedGoogle Scholar
• Kreipke C W, Morgan N C, Petrov T, Rafols J A. Calponin and caldesmon cellular domains in reacting microvessels following traumatic brain injury. Microvasc Res 2006; 71(3)197–204
   PubMedGoogle Scholar
• Croall D E, Chacko S, Wang Z. Cleavage of caldesmon and calponin by calpain: substrate recognition is not dependent on calmodulin binding domains. Biochim Biophys Acta 1996; 1298(2)276–284
   PubMedGoogle Scholar
• Arundine M, Aarts M, Lau A, Tymianski M. Vulnerability of central neurons to secondary insults after in vitro mechanical stretch. J Neurosci 2004; 24(37)8106–8123
   PubMedGoogle Scholar
• Ercan M, Inci S, Kilinc K, Palaoglu S, Aypar U. Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats. Neurosurg Rev 2001; 24(2 – 3)127–130
   PubMedGoogle Scholar
• Inci S, Ozcan O E, Kilinc K. Time-level relationship for lipid peroxidation and the protective effect of alpha-tocopherol in experimental mild and severe brain injury. Neurosurgery 1998; 43(2)330–335, discussion 335 – 6
   PubMed Web of Science ®Google Scholar
• Kontos H A, Wei E P. Superoxide production in experimental brain injury. J Neurosurg 1986; 64(5)803–807
   PubMedGoogle Scholar
• Roof R L, Hoffman S W, Stein D G. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol 1997; 31(1)1–11
   PubMedGoogle Scholar
• Caner H, Kwan A L, Bavbek M, et al. Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid haemorrhage. Acta Neurochir (Wien) 2000; 142(4)455–461
   PubMedGoogle Scholar
• Kaptanoglu E, Caner H H, Surucu H S, Akbiyik F. Effect of mexiletine on lipid peroxidation and early ultrastructural findings in experimental spinal cord injury. J Neurosurg 1999; 91(2 Suppl)200–204
   PubMedGoogle Scholar
• Monk J P, Brogden R N. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 1990; 40(3)374–411
   PubMedGoogle Scholar
• Nagasako S, Hayashibara M, Katagiri Y, Iwamoto K. Salivary excretion of mexiletine after bolus intravenous administration in rats. J Pharm Pharmacol 1992; 44(1)55–57
   PubMedGoogle Scholar
• Vaughan Williams E M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24(4)129–147
   PubMed Web of Science ®Google Scholar
• Ono K, Kiyosue T, Arita M. Comparison of the inhibitory effects of mexiletine and lidocaine on the calcium current of single ventricular cells. Life Sci 1986; 39(16)1465–1470
   PubMedGoogle Scholar
• Shirayama T, Inoue D, Inoue M, et al. Electrophysiological effects of sodium channel blockers on guinea pig left atrium. J Pharmacol Exp Ther 1991; 259(2)884–893
   PubMedGoogle Scholar
• Can A, Semiz O. Diethylstilbestrol (DES)-induced cell cycle delay and meiotic spindle disruption in mouse oocytes during in-vitro maturation. Mol Hum Reprod 2000; 6(2)154–162
   PubMedGoogle Scholar
• Crevits L, Hanse M C, Tummers P, Van Maele G. Antisaccades and remembered saccades in mild traumatic brain injury. J Neurol 2000; 247(3)179–182
   PubMedGoogle Scholar
• Gultekin S H, Smith T W. Diffuse axonal injury in craniocerebral trauma. A comparative histologic and immunohistochemical study. Arch Pathol Lab Med 1994; 118(2)168–171
   PubMedGoogle Scholar
• Graham D I, McIntosh T K, Maxwell W L, Nicoll J A. Recent advances in neurotrauma. J Neuropathol Exp Neurol 2000; 59(8)641–651
   PubMed Web of Science ®Google Scholar
• Lewen A, Li G L, Olsson Y, Hillered L. Changes in microtubule-associated protein 2 and amyloid precursor protein immunoreactivity following traumatic brain injury in rat: influence of MK-801 treatment. Brain Res 1996; 719(1 – 2)161–171
   PubMedGoogle Scholar
• Lewen A, Fredriksson A, Li G L, Olsson Y, Hillered L. Behavioural and morphological outcome of mild cortical contusion trauma of the rat brain: influence of NMDA-receptor blockade. Acta Neurochir (Wien) 1999; 141(2)193–202
   PubMedGoogle Scholar
• Saatman K E, Graham D I, McIntosh T K. The neuronal cytoskeleton is at risk after mild and moderate brain injury. J Neurotrauma 1998; 15(12)1047–1058
   PubMedGoogle Scholar
• Lee E J, Ayoub I A, Harris F B, Hassan M, Ogilvy C S, Maynard K I. Mexiletine and magnesium independently, but not combined, protect against permanent focal cerebral ischemia in Wistar rats. J Neurosci Res 1999; 58(3)442–448
   PubMedGoogle Scholar
• Povlishock J T, Jenkins L W. Are the pathobiological changes evoked by traumatic brain injury immediate and irreversible?. Brain Pathol 1995; 5(4)415–426
   PubMedGoogle Scholar
• Povlishock J T, Marmarou A, McIntosh T, Trojanowski J Q, Moroi J. Impact acceleration injury in the rat: evidence for focal axolemmal change and related neurofilament sidearm alteration. J Neuropathol Exp Neurol 1997; 56(4)347–359
   PubMed Web of Science ®Google Scholar
• Buki A, Koizumi H, Povlishock J T. Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Exp Neurol 1999; 159(1)319–328
   PubMedGoogle Scholar